Cuando los Antibióticos Fallan

Dos Casos Fatales de Infecciones por Achromobacter xylosoxidans en Pacientes Hospitalizados

Autores/as

DOI:

https://doi.org/10.23936/cienec.v5i22.150

Palabras clave:

Neumonía, Neumonía Asociada a la Atención Médica, Neumonía Bacteriana, COVID-19, Bacteriemia, Microbiología

Resumen

Introducción: Achromobacter xylosoxidans es una bacteria Gram-negativa oportunista que puede causar infecciones graves en pacientes con enfermedades subyacentes y en entornos de atención médica. La bacteria es conocida por su alta resistencia a los antibióticos, lo que presenta un desafío en la selección de opciones de tratamiento apropiadas. Casos clínicos: En el primer caso, un paciente con COVID-19 y una insuficiencia respiratoria aguda desarrolló neumonía y se aisló A. xylosoxidans en muestras respiratorias. A pesar del tratamiento con múltiples antibióticos, el paciente empeoró y falleció. En el segundo caso, un paciente postcolecistectomía desarrolló una bacteriemia por A. xylosoxidans que no respondió a varios tratamientos antibióticos. A pesar de los esfuerzos para controlar la infección, el paciente falleció. Conclusión: Estos casos destacan la importancia de la identificación temprana y el tratamiento adecuado de infecciones por A. xylosoxidans en pacientes con enfermedades subyacentes y en entornos de atención médica. La resistencia a los antibióticos de esta bacteria subraya la necesidad de un enfoque integral para el manejo de las infecciones, que incluya la identificación temprana y la implementación de medidas de control de infecciones en el entorno hospitalario. Se necesita más investigación para comprender la epidemiología y el impacto clínico de esta bacteria y para informar las estrategias para prevenir y controlar su propagación en los entornos de atención médica.

Citas

Grief SN, Loza JK. Guidelines for the Evaluation and Treatment of Pneumonia. Primary Care: Clinics in Office Practice. 2018;45(3): 485–503. https://doi.org/10.1016/j.pop.2018.04.001.

Sk?i?ková J. [Nosocomial pneumonia]. Vnitrni Lekarstvi. 2017;63(7–8): 518–526.

Henig O, Kaye KS. Bacterial Pneumonia in Older Adults. Infectious Disease Clinics of North America. 2017;31(4): 689–713. https://doi.org/10.1016/j.idc.2017.07.015.

Marrie TJ. Pneumonia in the Long-Term-Care Facility. Infection Control & Hospital Epidemiology. 2002;23(3): 159–164. https://doi.org/10.1086/502030.

Bates AS, Natarajan M, Reddy RV. Achromobacter xylosoxidans in idiopathic cystic bronchiectasis. BMJ case reports. 2018;11(1). https://doi.org/10.1136/bcr-2015-211610.

Aoyama S, Masaki A, Sakamoto Y, Takino H, Murase T, Ohshima K, et al. Achromobacter Infection Is Rare in Japanese Patients with Pulmonary B-cell Lymphoma. Internal medicine (Tokyo, Japan). 2018;57(6): 789–794. https://doi.org/10.2169/internalmedicine.9430-17.

Dupont C, Jumas-Bilak E, Doisy C, Aujoulat F, Chiron R, Marchandin H. Chronic Airway Colonization by Achromobacter xylosoxidans in Cystic Fibrosis Patients Is Not Sustained by Their Domestic Environment. Applied and environmental microbiology. 2018;84(23). https://doi.org/10.1128/AEM.01739-18.

de Castro RL, Lima N de A, Lino DO da C, Melgar TA. A Rare Case of Non-Prosthetic Aortic Valve Infectious Endocarditis Caused by Achromobacter xylosoxidans. The American journal of case reports. 2020;21: e923031. https://doi.org/10.12659/AJCR.923031.

Al-Asadi SA, Al-Kahachi RES, Alwattar WMA, Bootwala J, Sabbah MA. Genomic Insights into Achromobacter mucicolens IA Antibiotic Resistance. Microbiology spectrum. 2022;10(2): e0191621. https://doi.org/10.1128/spectrum.01916-21.

Damar-Çelik D, Nørskov-Lauritsen N, Özbek-Çelik B. Comparative in vitro activities of meropenem in combination with colistin, levofloxacin, or chloramphenicol against Achromobacter xylosoxidans strains isolated from patients with cystic fibrosis. Journal of global antimicrobial resistance. 2020;22: 713–717. https://doi.org/10.1016/j.jgar.2020.06.001.

Fluit AC, Bayjanov JR, Aguilar MD, Benaissa-Trouw B, Tunney MM, Westreenen M van, et al. Taxonomic position, antibiotic resistance and virulence factors of clinical Achromobacter isolates. Frontiers in bioscience (Scholar edition). 2022;14(2): 9. https://doi.org/10.31083/j.fbs1402009.

Gabrielaite M, Bartell JA, Nørskov-Lauritsen N, Pressler T, Nielsen FC, Johansen HK, et al. Transmission and Antibiotic Resistance of Achromobacter in Cystic Fibrosis. Journal of clinical microbiology. 2021;59(4). https://doi.org/10.1128/JCM.02911-20.

Pedersen MG, Olesen HV, Jensen-Fangel S, Nørskov-Lauritsen N, Wang M. Colistin resistance in Pseudomonas aeruginosa and Achromobacter spp. cultured from Danish cystic fibrosis patients is not related to plasmid-mediated expression of mcr-1. Journal of cystic fibrosis?: official journal of the European Cystic Fibrosis Society. 2018;17(2): e22–e23. https://doi.org/10.1016/j.jcf.2017.12.001.

Pongchaikul P, Santanirand P, Antonyuk S, Winstanley C, Darby AC. AcGI1, a novel genomic island carrying antibiotic resistance integron In687 in multidrug resistant Achromobacter xylosoxidans in a teaching hospital in Thailand. FEMS microbiology letters. 2020;367(14). https://doi.org/10.1093/femsle/fnaa109.

Abbott I, Peleg A. Stenotrophomonas, Achromobacter, and Nonmelioid Burkholderia Species: Antimicrobial Resistance and Therapeutic Strategies. Seminars in Respiratory and Critical Care Medicine. 2015;36(01): 099–110. https://doi.org/10.1055/s-0034-1396929.

Marion-Sanchez K, Pailla K, Olive C, Le Coutour X, Derancourt C. Achromobacter spp. healthcare associated infections in the French West Indies: a longitudinal study from 2006 to 2016. BMC Infectious Diseases. 2019;19(1): 795. https://doi.org/10.1186/s12879-019-4431-3.

Parra-Vera HJ, Farfán-Cano GG, Buele-Chica DC. Panorama microbiológico de Achromobacter spp. Como potencial agente infeccioso - Microbiological overview of Achromobacter spp. As a potential infectious agent. Investigatio. 2023;20: 74–85. https://doi.org/10.31095/investigatio.2023.20.6.

Toribio-Dionicio C, Cubas-Guzmán D, Guerra-Canchari P, García-Sánchez V, Córdova-Calderón W. Pulmonary Infections and Surgical Complications in a Young Girl with Signal Transducer and Activator of Transcription 3 Loss-of-Function Mutation Hyperimmunoglobulin E Syndrome: A Case Report. Pediatric allergy, immunology, and pulmonology. 2021;34(1): 33–37. https://doi.org/10.1089/ped.2020.1225.

Farfán-Cano GG, Silva Rojas GA. Achromobacter xylosoxidans as emerging pathogen in healthcare settings: A mini review. Narra X. 2023;1(1). https://doi.org/10.52225/narrax.v1i1.74.

Pérez Barragán E, Sandino Pérez J, Corbella L, Orellana MA, Fernández-Ruiz M. Achromobacter xylosoxidans bacteremia: clinical and microbiological features in a 10-year case series. Revista Espanola De Quimioterapia: Publicacion Oficial De La Sociedad Espanola De Quimioterapia. 2018;31(3): 268–273.

Ghali MGZ, Kim MJ. Trimethoprim-sulfamethoxazole-induced hyponatremia in an elderly lady with Achromobacter xylosoxidans pneumonia: Case report and insights into mechanism. Medicine. 2020;99(33): e20746. https://doi.org/10.1097/MD.0000000000020746.

Lebeaux D, Merabishvili M, Caudron E, Lannoy D, Van Simaey L, Duyvejonck H, et al. A Case of Phage Therapy against Pandrug-Resistant Achromobacter xylosoxidans in a 12-Year-Old Lung-Transplanted Cystic Fibrosis Patient. Viruses. 2021;13(1). https://doi.org/10.3390/v13010060.

Pouch SM, Patel G, the AST Infectious Diseases Community of Practice. Multidrug?resistant Gram?negative bacterial infections in solid organ transplant recipients—Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clinical Transplantation. 2019;33(9). https://doi.org/10.1111/ctr.13594.

Swenson CE, Sadikot RT. Achromobacter Respiratory Infections. Annals of the American Thoracic Society. 2015;12(2): 252–258. https://doi.org/10.1513/AnnalsATS.201406-288FR.

Spierer O, Monsalve PF, O’Brien TP, Alfonso EC, Gologorsky D, Miller D. Clinical Features, Antibiotic Susceptibility Profiles, and Outcomes of Infectious Keratitis Caused by Achromobacter xylosoxidans. Cornea. 2016;35(5): 626–630. https://doi.org/10.1097/ICO.0000000000000798.

Habib S, Fuca N, Azam M, Siddiqui AH, Rajdev K, Chalhoub M. Achromobacter xylosoxidans/denitrificans bacteremia and subsequent fatal Escherichia coli/Streptococcus anginosus pleural empyema. Respiratory Medicine Case Reports. 2018;25: 311–313. https://doi.org/10.1016/j.rmcr.2018.10.010.

Aoyama S, Masaki A, Sakamoto Y, Takino H, Murase T, Ohshima K, et al. Achromobacter Infection Is Rare in Japanese Patients with Pulmonary B-cell Lymphoma. Internal medicine (Tokyo, Japan). 2018;57(6): 789–794. https://doi.org/10.2169/internalmedicine.9430-17.

Issue 22

Descargas

Publicado

2023-08-28

Cómo citar

Zúñiga-Vinueza, A. M. ., Farfan-Cano, G. G., & Rodriguez-Hinojosa, I. A. (2023). Cuando los Antibióticos Fallan: Dos Casos Fatales de Infecciones por Achromobacter xylosoxidans en Pacientes Hospitalizados. Ciencia Ecuador, 5(22), 1-6. https://doi.org/10.23936/cienec.v5i22.150

Artículos más leídos del mismo autor/a